PAVmed
PAVM
20 hedge funds and large institutions have $5.2M invested in PAVmed in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 13 closing their positions.
1,079% more capital invested
Capital invested by funds: $441K → $5.2M (+$4.76M)
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
33.99% more ownership
Funds ownership: 0.22% → 34.21% (+34%)
29% less funds holding
Funds holding: 28 → 20 (-8)
46% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSC
Two Seas Capital
Rye,
New York
|
+$4.37M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$58.2K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.5K |
| 4 |
SS
SBI Securities
Tokyo,
Japan
|
+$596 |
| 5 |
Morgan Stanley
New York
|
+$38 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$68.6K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$23.7K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$15.1K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$15K |
| 5 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$14.4K |
PAVM Hedge Fund Activity: Q1 2026 in Review
20 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in PAVmed (PAVM) for Q1 2026, worth a combined $5.2M — up 1,079% from $441K a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of PAVM and 7 opened new positions — a net loss of 6 holders — while 3 trimmed existing stakes and 9 added.
The largest buyer was Two Seas Capital, opening a new position worth an estimated $4.37M. The largest seller was UBS Group, cutting an estimated $68.6K.
- 20 institutional investors held PAVmed (PAVM) as of Q1 2026, down from 28 in Q4 2025.
- Funds reported $5.2M of PAVmed stock for Q1 2026, up 1,079% quarter-over-quarter.
- 7 funds opened new PAVmed positions in Q1 2026 and 13 closed out, a net change of -6 holders.
- The largest PAVmed buyer in Q1 2026 was Two Seas Capital, an estimated $4.37M added.
- The largest PAVmed seller in Q1 2026 was UBS Group, an estimated $68.6K sold.
Based on aggregated 13F filings for Q1 2026.